Unapproved Substance Evidence Critique
FDA · TGA · WADA · peer-reviewed literature Updated May 2026 Reviewed by Allmeds AI Pharmacist

BPC-157 Benefits: What's Claimed and What Published Studies Actually Show

BPC-157 is widely marketed for injury recovery, tendon and ligament healing, gut healing, and anti-inflammatory effects. It is not FDA-approved for any of these uses. Most of the published evidence is from animal preclinical studies. Human safety and efficacy data are limited, methodologically weak, and not sufficient for regulator approval. This page contrasts marketing claims with published evidence.

BPC-157 is not FDA-approved for any benefit claim. Marketing describes broad healing effects (tendon, ligament, gut, anti-inflammatory), but the supporting evidence is overwhelmingly animal preclinical. Human clinical safety and efficacy data are very limited. The FDA has flagged BPC-157 among compounded substances that may present significant safety risks.

Key Takeaways

  • BPC-157 is not FDA-approved for any marketed benefit.
  • Most of the published evidence is animal preclinical: rat and mouse models of tendon, ligament, gut, and wound healing.
  • Human clinical safety and efficacy data are limited and methodologically weak.
  • The FDA has identified BPC-157 among compounded substances that may present significant safety risks (immunogenicity, impurity, characterisation complexity).
  • WADA prohibits BPC-157 use in competitive sport.

What marketing typically claims about BPC-157

Online sellers and clinics market BPC-157 for accelerated tendon and ligament healing, gut healing (gastric ulcer, inflammatory bowel), reduced inflammation, joint repair, neuroprotection, and recovery from injury. These claims are made in marketing material, blog posts, and influencer content.

What the published evidence actually shows

The published evidence base for BPC-157 is dominated by animal preclinical work from the Sikiric laboratory and collaborators, primarily in rats. Reported animal findings include accelerated healing of transected Achilles tendon, medial collateral ligament, gastric mucosa, and skin wounds. Mechanistic claims involve effects on growth factor signalling, nitric oxide pathways, and angiogenesis.

Human studies of BPC-157 are very limited. There are no large, controlled, peer-reviewed human trials supporting the marketed benefit claims. Sports-medicine and toxicology reviews have characterised the human evidence as insufficient to establish either safety or efficacy.

What the regulators say

The FDA has explicitly identified BPC-157 among substances that may present significant safety risks when compounded. The FDA cites potential immunogenicity, peptide impurity, API characterisation complexity, and the absence of safety-related information for proposed routes of administration. The FDA position notes the agency lacks sufficient information to know whether BPC-157 would harm humans.

The TGA does not list BPC-157 on the Australian Register of Therapeutic Goods for the promoted uses.

WADA prohibits BPC-157 in competitive sport.

Check your medications before any change

Allmeds scans interactions across your full list. Free for individuals; team plans available.

Try it free → Talk to Sales

Common Questions

Does BPC-157 actually heal tendons and ligaments?

Animal model studies (mostly rats) have reported faster healing of transected tendons, ligaments, and other tissues with BPC-157. These findings have not been replicated in adequately powered, controlled human trials, and BPC-157 is not FDA-approved for any healing indication. Speak to a sports-medicine clinician about evidence-based options.

What does the FDA say about BPC-157 benefits?

The FDA does not endorse any BPC-157 benefit claim. The agency has flagged BPC-157 among compounded substances that may present significant safety risks, citing immunogenicity, impurity, and characterisation concerns.

Is BPC-157 backed by human studies?

Human studies are very limited. Sports-medicine and toxicology reviews have characterised the human evidence as insufficient to support marketed benefit claims or to establish safety for typical use.

Why is BPC-157 used despite the regulator position?

BPC-157 is widely marketed online and through some clinics, often without disclosing the FDA position or the limits of human evidence. Patients should discuss any planned use with a clinician who can review the regulator position and the limits of published evidence.

References

  1. Sikiric P et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):857-865. Source.
  2. Seiwerth S et al. BPC 157 and standard angiogenic growth factors. Curr Pharm Des. 2018;24(18):1972-1989. Source.
  3. U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Source.
  4. World Anti-Doping Agency. WADA Prohibited List. Source.
  5. Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG). Source.
Not medical advice. This page summarises regulator statements and peer-reviewed literature for general information. It is not a substitute for professional medical advice. Speak to your doctor or pharmacist before starting, stopping, or changing any medicine.